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Arnaud Chiche1, Hugues Georges1, Yazdan Yazdanpanah2 and Olivier Leroy1Abstract
Background: The impact of highly active antiretroviral therapy (HAART) in HIV-infected patients admitted to the
intensive care unit (ICU) remains controversial. We evaluate impact of HAART prescription in HIV-infected patients
admitted to the ICU of Tourcoing Hospital from January 2000 to December 2009.
Results: There were 91 admissions concerning 85 HIV-infected patients. Reasons for ICU admission were an
AIDS-related diagnosis in 46 cases (51%). Fifty two patients (57%) were on HAART at the time of ICU admission,
leading to 21 immunovirologic successes (23%). During the ICU stay, HAART was continued in 29 patients (32%),
and started in 3 patients (3%). Only one patient experienced an adverse event related to HAART. Mortality rate in
ICU and 6 months after ICU admission were respectively 19% and 27%. Kaplan-Meier estimates of the cumulative
unajusted survival probability over 6 months were higher in patients treated with HAART during the ICU stay (Log
rank: p = 0.04). No benefit of HAART in ICU was seen in the adjusted survival proportion at 6 months or during ICU
stay. Prescription of HAART during ICU was associated with a trend to lower incidence of new AIDS-related events
at 6 months (respectively 17% and 34% with and without HAART, p = 0.07), and with higher incidence of
antiretroviral resistance after ICU stay (respectively 25% and 7% with and without HAART, p = 0.02).
Conclusions: Our results suggest a lower death rate over 6 months in critically ill HIV-infected patients taking
HAART during ICU stay. The optimal time to prescribe HAART in critically ill patients needs to be better defined.
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Highly active antiretroviral therapy (HAART) has
increased the life expectancy of patients who are
infected with the human immunodeficiency virus (HIV)
and has reduced the incidence of illnesses associated
with the acquired immunodeficiency syndrome (AIDS).
HIV-infected adults with CD4 cell count greater than
500 cells/mm3 on long-term combination antiretroviral
therapy reach same mortality rates as the general popu-
lation [1]. Survival of HIV-infected patients admitted to
the intensive care unit (ICU) has been evaluated in a* Correspondence: agnesmeybeck@yahoo.fr
1Service de Réanimation et Maladies Infectieuses, Hôpital de Tourcoing, 135
rue du Président Coty, Tourcoing BP 619, France
3Service de Réanimation et Maladies Infectieuses, Centre Hospitalier Dron,
128 rue du Président Coty, Tourcoing 59200, France
Full list of author information is available at the end of the article
© 2012 Meybeck et al.; licensee BioMed Centr
Commons Attribution License (http://creativec
reproduction in any medium, provided the ornumber of studies [2-6]. Most of these studies have
shown improved survival since the late 1990s for HIV
infected patients, associated with the advent of HAART.
But whether or not the improved survival is dependent
of the use of HAART remains controversial [5-7]. Chan-
ging practices of ICU care and decrease of AIDS-related
admissions may explain survival improvement [2,8].
Very few previously published studies have reported
data on the use of HAART in the ICU [9-11]. There are
no randomized clinical trials and no consensus guidelines
to assist in decisions regarding the use of HAART in the
ICU [11]. Early prescription of HAART in ICU might
decrease patient morbidity and mortality by restoring
pathogen specific immune responses and speeding immune
reconstitution. On the other hand, prescription of HAART
in critically ill patients might result in higher morbidity andal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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drug-drug interactions, increasing the frequency of
immune reconstitution and inflammatory syndrome (IRIS).
We conducted a retrospective cohort study of all con-
secutive cases of HIV-infected patients admitted to the
ICU from January 2000 to December 2009 at Tourcoing
Hospital. The aim of this study was to evaluate the
impact of HAART prescription prior to ICU and during
ICU stay.
Methods
Patients and hospital setting
We conducted a retrospective cohort study of all con-
secutive cases of HIV-infected patients admitted to the
16-bed ICU of Tourcoing Hospital from January 2000 to
December 2009. As it was an observational retrospective
study, in accordance with French law, neither approval
of the ethics committee nor informed consent was
required. If patients were admitted to the ICU more
than one time during any hospitalisation, only data from
admissions separated by > 90 days were considered inde-
pendent events and were included in the analysis.
Data collection and baseline data
Data on HIV infection and on ICU stay were obtained
retrospectively, using case-notes and computer database.
Data obtained included age, sex, race, the indication(s)
for ICU admission, underlying clinical conditions, pres-
ence of comorbidities, severity of illness at ICU admis-
sion. Admission was considered AIDS-related if the
main admission diagnosis was an AIDS-defining condi-
tion (1993 Centers for Disease Control Classification
System for HIV-Infected Adults) [12]. The underlying
clinical conditions were classified according to the cri-
teria proposed by McCabe and Jackson in 3 categories:
non fatal (5 year survival not affect by underlying dis-
ease), ultimately fatal (not expected to survive more than
5 years), and rapidly fatal (not expected to survive more
than 1 year) [13]. The severity of illness at the time of
ICU admission was assessed by SAPS II and Glasgow
Coma Score [14,15]. The SAPS II includes 12 physiology
variables including Glasgow Coma Score, and age, type
of admission (scheduled surgical, unscheduled surgical,
or medical), and three underlying disease variable
(acquired immunodeficiency syndrome, metastatic can-
cer, and hematologic malignancy). Neurological and
mental status was stratified according to Glasgow Coma
Score. The following therapeutic modalities in ICU were
recorded: invasive or noninvasive mechanical ventilation,
hemodialysis or hemofiltration, and use of vasoactive
drugs.
The following data on HIV-infection were recorded
for each case at ICU admission: risk factor for HIV, HIV
disease staging according to CDC Classification Systemfor HIV-Infected Adults (Category A: asymptomatic,
acute HIV, or persistent generalized lymphadenopathy;
Category B: symptomatic conditions not A or C; Cat-
egory C: AIDS-indicator conditions), CD4 cell count and
plasma HIV viral load if available within 6 months of ad-
mission. The mean time between determination of CD4
cell count and plasma HIV viral load and admission in
ICU was 32 days. During ICU stay, we recorded new
AIDS-defining event and IRIS occurence. IRIS was
defined as a paradoxical deterioration in clinical status
or laboratory findings after the initiation of antiretroviral
therapy without another attribuable cause.
The following data on antiretroviral therapy were
recorded: HAART prior and during ICU stay. We col-
lected regimen, duration and adverse effects. HAART
was defined as a combination of 3 or more antiretroviral
drugs belonging to at least 2 classes among the follow-
ing: protease inhibitors (PIs), nucleoside reverse tran-
scriptase inhibitors (NRTIs), and nonnucleoside reverse
transcriptase inhibitors (NNRTIs). No other antiretro-
viral combination than HAART was prescribed in our
cohort.
After the ICU stay, the following data were recorded:
CD4 cell count and viral load at 3, 6, and 12 months
after ICU admission, occurence of a new AIDS defining
event, occurence of IRIS, change in HAART prescrip-
tion, emergence of antiretroviral-resistance at any time
during a 12 months period following ICU admission.
Outcome measures
Our primary outcomes of interest were in ICU and 6-
month mortality. Secondary outcomes of interest were
the occurrence of a new AIDS related event, immunovir-
ological response, adverse event of antiretroviral therapy,
emergence of resistance. Immunovirological success was
defined as viral load < 200 copies/ml and CD4 > 200
cells/mm3.
Statistical analyses
Analyses were performed to identify predictive factors of
ICU and 6-month mortality. All collected variables con-
cerning underlying disease, severity of illness, care in
ICU, and HIV-infection were analysed. Categorical vari-
ables were compared using Chi-square test or Fisher’s
exact test when Chi-square was not appropriate. Con-
tinuous variables were compared using Student’s t test
or Mann–Whitney test when appropriate. All variables
attaining an α value of 0.05 were included in a multiple
logistic regression analysis model with a stepwise selec-
tion of variables to identify predictive factors of ICU and
6-month mortality. Variables that originate a multicoli-
nearity were eliminated. The quality of the model was
evaluated through its measures of sensitivity and specifi-
city with establishment of a ROC curve. Kaplan Meier
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tality over 6 months. Log rank test was used to compare
differences in survival between two groups (no HAART
use in ICU vs HAART use in ICU). Differences between
groups were considered to be significant for variables
yielding a p value ≤ 0.05.
Results
Demographic and clinical characteristics
There were 91 ICU admissions concerning 85 HIV-
infected patients. Demographic and clinical characteris-
tics of our patients are shown Table 1. The majority of
the ICU cohort consisted of men (n = 61, 67%), and was
ever diagnosed with AIDS (n = 69, 76%). Patients were
equally likely to be heterosexual (n = 31, 34%), orTable 1 Characteristics of the patients and clinical data depen
Characteristics and clinical data Total (n = 91) w
Characteristics
Age (in years) 42 ± 10
Sex (M/F) 61/30
SAPS II on admission 47 ± 20
Glasgow score 12 ± 4






Initial HIV diagnosis 17 (19)
Stage C 69 (76)
CD4 count at admission (cells/mm3) 112 [1–935]
Viral load at admission (log10) 3.38 ± 1.60








Mechanical ventilation (MV) 45 (49)
Duration of ventilation (days) 5 ± 10
Renal replacement 7 (8)
Vasoactive drugs 22 (24)
Duration of vasoactive drugs (days) 1 ± 2
ICU length of stay (days) 8 ± 10
Death in ICU 17 (19)
*Data are presented as No. (%) or mean ± SD, except for CD4 cell count which are ehomosexual (n = 31, 34%). Median CD4 cell count at
ICU admission was 112/mm3 [1–935]. The ICU admis-
sion represented the initial HIV diagnosis for 19% of the
cases. Respiratory failure and neurologic disorder were
the most frequent reasons for ICU admission (51% and
27% respectively). The ICU admissions were motivated
by AIDS-associated diagnosis in 46 patients (51%).
HAART adverse events led to ICU admission in 4
patients. Mechanical ventilation was needed in 45
patients (49%) for a mean duration of 5 ± 10 days. The
mean length of ICU stay was 8 ± 10 days.
Patients who received HAART in ICU were similar to
those who did not with respect to age, gender, mean
SAPS II, and Glasgow score. Patients who received
HAART in ICU were less likely to be ignorant of theirding on HAART use during ICU stay*
ithout HAART (n= 59) with HAART (n= 32) p
42 ± 9 43± 11 0.98
40/19 21/11 0.99
48 ± 21 46 ± 17 0.83
12 ± 5 13± 4 0.24
28 (47) 18 (56) 0.51
16 (27) 9 (28) 0.99
6 (10) 4 (13) 0.99
9 (15) 1 (3) 0.09
16 (27) 1 (3) 0.004
43 (73) 26 (81) 0.85
100 [2–935] 161 [1–822] 0.68
3.86 ± 1.51 2.63 ± 1.45 0.0005






29 (49) 16 (32) 0.87
5 ± 11 5 ± 9 0.81
3 (5) 4 (13) 0.33
15 (25) 7 (22) 0.99
1 ± 2 1 ± 2 0.99
8 ± 11 8 ± 9 0.43
12 (20) 5 (16) 0.78
xpressed as median [range].






Characteristics at ICU admission
Age 40± 9 42± 9 0.19
Sex (M/F) 8/17 19/36 0.99
SAPSII on admission 55 ± 25 42 ± 16 0.02
Glasgow on admission 10 ± 5 13± 4 0.05
HIV infection
Initial HIV diagnosis 8 (32) 6 (11) 0.03
Stage C 20 (80) 43 (78) 0.99
CD4 count at admission (/mm3) 154± 201 215 ± 198 0.21
AIDS related diagnosis at ICU
admission
16 (64) 24 (44) 0.15
Care in ICU
Mechanical ventilation 19 (76) 20 (36) 0.0015
Duration of ventilation (days) 10 ± 13 3 ± 8 0.0001
Vasoactive drugs 6 (24) 5 (9) 0.09
Duration of vasoactive drugs
use (days)
1.7 ± 2.5 0.6 ± 1.3 0.006
Use of HAART
HAART at ICU admission 11 (44) 35 (64) 0.14
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cantly lower mean log viral load (2.63 ± 1.45 log copies/
ml vs 3.86 ± 1.51 log copies/ml, p = 0.0005). Median CD4
cell count at admission was similar in both groups.
Risk factors for mortality
Mortality rate in ICU, and 6 months after ICU admis-
sion were respectively 19% and 27%. Results for univari-
ate analysis for ICU and 6-month outcomes are
presented respectively in Table 2 and Table 3.
By univariate analysis, the factors associated with ICU
mortality were high SAPS II score, low Glasgow score,
use of mechanical ventilation, prolonged duration of
mechanical ventilation, and of catecholamine prescrip-
tion. Patient with undiagnosed HIV were more likely to
die in ICU. By univariate analysis, the factors associated
with 6-month mortality were similar to those associated
with ICU mortality. Neither history of HAART use prior
to ICU admission, nor use of HAART during ICU stay
was associated with ICU and 6-month survival.
Results for multivariate analysis for ICU and 6-month
mortality are presented respectively in Table 4 and
Table 5. By multivariate analysis, the only factor inde-






Characteristics at ICU admission
Age (in years) 40 ± 9 43 ± 10 0.13
Sex (M/F) 7/10 23/51 0.57
Glasgow score 8 ± 5 13 ± 4 0.0003
HIV infection
Initial HIV diagnosis 7 (37) 10 (14) 0.015
Stage C 13 (76) 56 (76) 0.99
CD4 count at admission
(cells/mm3)
120± 98 206 ± 209 0.38
AIDS related diagnosis at ICU
admission
11 (65) 35 (47) 0.28
Care in ICU
Mechanical ventilation 17 (100) 28 (38) <0.0001
Duration of ventilation (days) 12 ± 13 4 ± 9 <0.0001
Vasoactive drugs 5 (29) 8 (11) 0.06
Duration of vasoactive drugs
use (days)
2.5 ± 2.7 0.7 ± 1.7 <0.0001
Use of HAART
HAART at ICU admission 6 (38) 46 (62) 0.09
} immunovirological success at
ICU admission
2 (12) 19 (26) 0.34
HAART during ICU stay 5 (29) 27 (36) 0.78
*Data are presented as No. (%) or mean ± SD. }Immunovirological success was
defined as viral load < 200 copies/ml and CD4 > 200 cells/mm3.
immunovirological success at
ICU admission
3 (12) 17 (31) 0.096
HAART during ICU stay 9 (36) 21 (38) 0.99
*Data are presented as No. (%) or mean ± SD.score (OR= 1.05 per point; 95%CI: 1.02-1.08; p = 0.001).
SAPS II score and AIDS-associated diagnosis were inde-
pendently associated with 6-month mortality (respect-
ively OR= 1.05 per point; 95%CI: 1.01-1.06; p = 0.001
and OR= 2.9, 95%CI: 1.01-8.31; p = 0.04). The quality of
the model has been evaluated through its measures of
sensitivity and specificity with establishment of a ROC
curve, the area under the curve being 0.739 (Figure 1).Use of HAART
At the time of ICU admission, 52/91 (57%) of patients
were on HAART, leading to only 21 (23%) immunoviro-
logical successes. A combination of two nucleoside/nu-
cleotide reverse transcriptase inhibitor (NRTI) and one
protease inhibitor (PI) was the most common prescribed
regimen (n = 31/52, 59%).Table 4 Multivariate predictors of ICU survival*
Variables Adjusted OR (95% CI) p value
SAPS II on admission
(per 1 point of increment)
1.05 (1.02-1.08) 0.001
*The retained variables for the multivariate analysis were those the adjustment
of which had a medical or biological meaning, eliminating that originate a
multicolinearity. Variables were retained when their effect had a P value less
than 0.05.




SAPS II on admission
(per 1 point of increment)
1.05 (1.01-1.06) 0.001
AIDS related diagnosis 2.9 (1.01-8.31) 0.04
*The retained variables for the multivariate analysis were those the adjustment
of which had a medical or biological meaning, eliminating that originate a
multicolinearity. Variables were retained when their effect had a
P value less than 0.05.
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32 patients (35%), and initiated in ICU in 3 patients (3%).
In patients already receiving antiretroviral therapy at ICU
admission, HAART was continued in 26 patients (50%),
modified in 3 patients (6%), stopped in 23 patients (44%).
HAART interruption was motivated by a severe side effect
in 4 patients. In 19 patients, no justification for HAART
discontinuation was found in the patient chart. HAART
was stopped despite immunovirological success in 9
patients. The 3 patients who changed HAART, replaced
another boosted protease inhibitor by the combination
lopinavir-norvir, available in liquid form. The median
delay between ICU admission and HAART prescription
was 0 day [0–38]. In case of HAART initiation in ICU, this
delay was prolonged: 19 [2–38] days. The duration of
HAART in ICU was 5± 4 days. Patients treated with
HAART in ICU spent 76% of their ICU stay on HAART.
The most commonly prescribed regimen in ICU was the
combination of two NRTI and one PI (n= 24/32, 75%).
All patients who received HAART during ICU stay
continued HAART after ICU stay. After ICU discharge,
















Area under ROC curve = 0.7393
Figure 1 ROC curve evaluating quality of the model including SAPS II
The quality of the multiple logistic regression analysis model was evaluated
of a ROC curve. Aera under the ROC curve was 0.7393.because of drug interaction in 3 patients, adverse event
occurence in 2 patients, virological failure in one patient,
addition of enfuvirtide in one patient. No motivation was
found in one patient. HAART was initiated (n= 14) or
reintroduced (n= 15) in patients not treated in ICU after a
mean delay of 19± 22 days after ICU release. The most
common prescribed regimen after ICU stay was the com-
bination of two NRTI and one PI (n= 38/61, 62%).
Impact of HAART on survival
The mortality rate was not significantly different at ICU
discharge and at 6 months according to the use of
HAART during the ICU stay: respectively 16% vs 20%
with and without HAART at ICU discharge, and 28% vs
27% respectively with and without HAART at 6 months.
Kaplan-Meier estimates of the cumulative unadjusted
survival probability over 6 months were significantly
higher in the group of patients treated with HAART
during the ICU stay (Log rank test, p = 0.04) (Figure 2).
But, no benefit of HAART was seen specifically in the
adjusted survival proportion at 6 months or during ICU
stay (Table 2 and Table 4).
Impact of HAART on AIDS progression and
immunovirologial response
During ICU stay, a new AIDS related event was diag-
nosed in 3 patients (9%) treated with HAART, and in 5
patients (8%) not treated with HAART. At 6 months,
new AIDS related events tended to be less frequent in
the group of patients treated with HAART in ICU, re-
spectively 17% vs 34% with and without HAART
(p = 0.07)..50 0.75 1.00
and AIDS-related diagnosis to determine 6-month mortality risk.
through its measures of sensitivity and specificity with establishment
Figure 2 The effect of the prescription of antiretroviral therapy in ICU on 6-month cumulative survival. Kaplan-Meier estimates of the
cumulative unajusted survival probability over 6 months were higher in patients with HAART (grey line) vs without HAART(black line) during the
ICU stay (Log rank: p = 0.04).
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significant difference between the two groups (with vs
without HAART) at any time of the year following ICU
admission. Median CD4 cell count at 12 months reached
1309 [365–2254] cells/mm3 and 385 [99–605] cells/mm3
respectively with and without HAART (p = 0.23). Mean
log10 viral load was significantly lower at 3 and 6 months
in patients treated with HAART while in ICU
(2.06 ± 0.78 vs 3.16 ± 1.46 copies/ml with and without
HAART at 3 months, p = 0.02, and 2.42 ± 0.68 vs
3.37 ± 1.36 copies/ml with and without HAART at
6 months, p = 0.03). One year after ICU admission,
immunovirological success was achieved in 25% of
patients treated with HAART and in 16% of patients not
treated with HAART (p = 0.25).
A resistance to an antiretroviral molecule was diag-
nosed after ICU in 8 patients (25%) treated with
HAART, and in 4 patients (7%) not treated with HAART
(p = 0.02). A history of HAART prior to ICU and an
immunovirologic failure at ICU admission were reported
respectively in 12 and 5 patients diagnosed with anti-
retroviral resistance after ICU.
Tolerance of HAART
In ICU, a side effect motivating interruption of HAART
was reported in one patient, who suffered from severe
anemia while treated with zidovudine. After ICU stay, 21
adverse events motivating interruption or change of
HAART were reported after a mean duration of treat-
ment of 107 ± 112 days. The incidence of adverse events
after ICU was not different according to the timing of
HAART prescription, during or after the ICU stay. An
IRIS was diagnosed in 2 patients (2.2%). Both IRIS
occured after ICU stay, respectively 25 days and 45 days
after ICU admission. One patient received HAART in
ICU. The other one began HAART the day he left the
ICU, 7 days after his admission.Discussion
In our cohort of HIV-infected patients admitted to the
ICU, the only independent predictor of ICU outcome
was severity of acute illness assessed by SAPS II score at
ICU admission. Two factors were independent predic-
tors of decreased 6-month survival: SAPS II score and
AIDS-associated diagnosis at ICU admission. Use of
HAART during ICU stay improved unadjusted survival
at 6 months. But no benefit was seen specifically in the
adjusted survival proportion at 6 months or during ICU
stay. Use of HAART during ICU stay tended to reduce
AIDS progression. Tolerance of HAART in ICU was
good. IRIS was rare. Prescription of HAART during ICU
stay was associated with higher incidence of antiretro-
viral resistance after ICU stay.
In our cohort, risk factors for ICU mortality were con-
sistent with factors previously identified in the literature;
these relate to the extent of organ dysfunction rather
than HIV-related characteristics [6,7,16]. Severity of
acute illness assessed by various scores (APACHE-II
score, SAPS-II), need for mechanical ventilation, or cat-
echolamine predicted higher mortality rate in ICU
[2,3,6,7,16,17]. Low serum albumin level has been asso-
ciated with increased mortality rate in ICU in several
studies [6,7,17,18].
In our series, AIDS-related disease at the time of ICU
admission was associated with a higher 6-month mortal-
ity rate. Other previous reports demonstrated an impact
on long term survival of AIDS-associated diagnosis in
the ICU [2,6,17]. Morris A et al. reported that the
patients with a non-AIDS-associated diagnosis had a
dramatically improved median survival compared with
those with an AIDS-associated diagnosis [6]. Khouli H
et al. showed HIV-related illness to be a significant inde-
pendent predictor of increased hospital mortality [17].
Among the HIV-related characteristics, the CD4 cell
count may be a predictor of long-term outcome [19].
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cant relationship between the CD4 cell count and sur-
vival [4,6,20].
Concerning HAART prescription, almost two thirds of
our patients were on HAART at the time of ICU admis-
sion. But only 23% of the patients have achieved immu-
novirological success. Prior HAART was continued in
ICU in only 53% of the patients, and HAART was al-
most never initiated in ICU. By multivariate analysis, the
use of HAART prior to ICU admission and during ICU
stay did not independently affect ICU or 6-month sur-
vival. But the log rank test suggests a lower death rate
over 6-months in patients treated with HAART in ICU.
The discrepancy between log-rank curves and the multi-
variate analysis may be due to potential confounders.
Patients without HAART in ICU were more likely to be
ignorant of their HIV infection and tended to suffer
more often from an opportunistic disease. This could in-
fluence the prognosis. Patients with HAART in ICU
tended to experience fewer AIDS-associated diagnosis
during the 6-month follow-up period. Improved immune
function and increased CD4 cell count following
HAART could explain the reduction of AIDS progres-
sion in case of HAART use in ICU. Published data that
have assessed the impact of HAART in ICU are few.
Several retrospective studies have reported an improve-
ment of survival of HIV-infected patients admitted in
ICU in the last decade, since the advent of HAART
[2,4,6]. But the impact of HAART on survival is intrin-
guing. The decrease in mortality could be a result of a
change in the spectrum of admission diagnosis as non
AIDS-associated diagnosis became more common and
were associated with a better survival than AIDS-
associated diagnosis. Powell K. et al. examined survival
to hospital discharge of HIV-infected patients admitted
to the ICU since the year 2000 [7]. They reported that
survival for critically ill HIV-infected patients continues
to improve in the current era of HAART. This improve-
ment appeared to be independent of the use of HAART.
Many advances in critical care practice (e.g., low tidal
volumes for patients with respiratory failure, tight gly-
cemic control, adjuvant corticosteroïds for certain condi-
tions, early goal-directed therapy for sepsis) have been
made across this last decade [21-23]. They could con-
tribute to outcome improvement of HIV infected
patients admitted in ICU.
None of these observational studies reported data on
the prescription of HAART during the ICU stay. Only
three retrospective studies have assessed the potential
benefit associated with administrating HAART in the
ICU. Morris et al. performed a retrospective study of 58
patients admitted to the ICU with Pneumocystis jirovecii
between 1996 and 2001 [24]. They found that patients
who were receiving HAART at the time of ICUadmission or had HAART started during the ICU stay
had a reduced mortality rate compared to those who did
not receive HAART. Another retrospective study con-
ducted in a Mexican ICU found HAART prior to admis-
sion or starting within one month after ICU discharge to
be the major protective factor for death [9]. In their co-
hort, Croda et al. reported a significantly better survival
of patients who began HAART during ICU stay com-
pared to patients without HAART during ICU stay [10].
The potential benefit of HAART found in these three
studies could reflect the impact of early prescription of
HAART in the context of AIDS-defining diagnosis. An
AIDS-defining diagnosis motivated ICU admission in
51% of patients in our cohort and in up to 80% of
patients in the last study mentioned. But, in our popula-
tion, only 19% of patients had not been diagnosed with
HIV infection prior to their admission in ICU. A major-
ity of our patients had history of HAART. The very
small proportion of patients initiating HAART in our
cohort could explain the lack of significant impact of
HAART prescription on prognosis. Recently, Zolopa
et al. conducted a prospective randomized study to com-
pared immediate HAART (within two days of study en-
rollment) to deferred HAART (between week 6 and
week 12) in HIV-patients diagnosed with acute AIDS-
related opportunistic infection [25]. Early HAART
resulted in less AIDS progression and death compared
to deferred HAART. Concurrent treatment of the op-
portunistic infection and HIV might increase the fre-
quency of IRIS and have a deleterious impact on
outcomes. Incidence and consequences of IRIS vary by
opportunistic infections and corticoid use [25-27]. In
case of cryptococcal meningitis, early initiation of
HAART resulted in increased rate of IRIS, and increased
mortality [26]. In case of tuberculosis, HAART started
during tuberculosis therapy resulted in lower mortality
despite higher incidence of IRIS [27]. In the setting of
the opportunistic infections observed in our cohort,
most particularly Pneumocystis pneumonia, IRIS occur-
ence was rare. Only one previous study conducted in
ICU has reported data on IRIS [10]. Among 278 HIV-
infected patients admitted in ICU, three patients with
tuberculosis developed IRIS during their ICU stay.
Our study is the first to report data on the use of
HAART after the ICU stay. In our cohort, patients not
receiving HAART in ICU initiated or restarted HAART
after a median delay of three weeks after ICU release.
This relatively short delay could have reduced the im-
pact of HAART prescription in ICU. The optimal time
to prescribe HAART in ICU patients (immediate treat-
ment vs early treatment after ICU discharge) needs to be
defined. The decision regarding when to administrate
antiretroviral therapy in critically ill HIV-patients must
balance the risk of HIV disease progression with the
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of HAART in ICU was good with only one patient (3%)
suffering from a side effect motivating interruption of
HAART. After ICU discharge, the incidence of adverse
events was not different according to the timing of
HAART prescription, during or after the ICU stay. Only
one previous study conducted in ICU has reported data
on HAART adverse effects. The incidence of side effects
demanding either switch in or discontinuation of
HAART was 18% [10]. Occurence of an adverse effect
had no impact on mortality.
Another concern about HAART prescription in ICU is
drug delivery. Most drugs are only available orally with
few liquid medications, and absorption is often unpre-
dictable in seriously ill patients. Multiple drug interac-
tions with HAART can result in either toxic or
subtherapeutic antiretroviral drug levels. In our cohort,
we did not practice any drug monitoring. But we
observed a higher proportion of antiretroviral drug re-
sistance after ICU discharge in patients treated with
HAART in ICU. Low antiretoviral drug concentrations
in critically ill patients could lead to selection of resistant
virus. Non compliance to HAART before ICU admission
could have contributed to the resistance. All patients
diagnosed with resistance after ICU have been exposed
to HAART. But we did not specifically evaluate adher-
ence to HAART.
Our study has several limitations in interpretation and
the ability to generalize from its results. We conducted
our study at a single institution. Clinical practice and
demographics may differ across institutions, and coun-
tries. As in any observational retrospective study, the
missing data could have reduced the strength of our
observations. Because of the study’s retrospective nature,
it is possible that patients receiving HAART differ in
some systematic way beyond the direct effects of the
medications. In our cohort, patients who received
HAART in ICU were less likely to be ignorant of their
HIV infection. Confounders may have affected our
observations. But the major limitations of our study are
the small size and heterogeneity of patients groups that
prevent adequate statistical analysis. Nevertheless, the
relatively short duration of inclusion time allowed stan-
dardized ICU care. All patients were admitted in ICU
during an era including tight glycemic control, protect-
ive ventilation in case of acute respiratory distress syn-
drome, corticosteroids in case of Pneumocystis
pneumonia or septic shock [21-23].
Conclusion
In our cohort of critically ill HIV-infected patients, bene-
fit of HAART administration during ICU stay was lim-
ited. The reticence of intensivists to use HAART and the
early prescription of HAART after ICU discharge mayhave reduced the impact of HAART use in ICU. Our
results support the need for prospective randomized
clinical trials to address the optimal timing to prescribe
HAART in critically ill patients. Future trials should pro-
vide antiretroviral drug monitoring and data on compli-
ance to HAART after ICU discharge.
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